---
document_datetime: 2025-02-27 13:28:44
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/welireg-epar-all-authorised-presentations_en.pdf
document_name: welireg-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.6524978
conversion_datetime: 2025-12-24 22:39:09.217828
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| MA (EU) number                    | (Invented) name   | Strength    | Pharmaceutical Form                   | Route of Administration   | Immediate Packaging                 | Pack size                                  |
|-----------------------------------|-------------------|-------------|---------------------------------------|---------------------------|-------------------------------------|--------------------------------------------|
| EU/1/24/1893/001 EU/1/24/1893/002 | Welireg Welireg   | 40 mg 40 mg | Film-coated tablet Film-coated tablet | Oral use Oral use         | blister (alu/alu) blister (alu/alu) | 30 tablets 90 (3 x 30) tablets (multipack) |